Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy

详细信息    查看全文

• 作者：Magali Sasso^&lowast ; ; ^{magali.sasso@echosens.com" class="auth_mail" title="E-mail the corresponding author} ; Sté ; phane Audi&egrave ; re^&lowast ; ; Astrid Kemgang^&dagger ; ; Farid Gaouar^&dagger ; ; Christophe Corpechot^&dagger ; ; Olivier Chazouill&egrave ; res^&dagger ; ; Cé ; line Fournier^&Dagger ; ; Olivier Golsztejn^§ ; ; Sté ; phane Prince^§ ; ; Yves Menu^§ ; ; Laurent Sandrin^&lowast ; ; Vé ; ronique Miette^&lowast ;
• 关键词：Ultrasound attenuation ; Controlled attenuation parameter (CAP) ; Liver ; Steatosis ; Steato-hepatitis ; Non-alcoholic fatty liver disease (NAFLD) ; Elastography ; Vibration-controlled transient elastography (VCTE) ; FibroScan
• 刊名：Ultrasound in Medicine & Biology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：42
• 期：1
• 页码：92-103
• 全文大小：1183 K

文摘

To assess liver steatosis, the controlled attenuation parameter (CAP; giving an estimate of ultrasound attenuation ∼3.5 MHz) is available with the M probe of the FibroScan. We report on the adaptation of the CAP for the FibroScan XL probe (center frequency 2.5 MHz) without modifying the range of values (100–400 dB/m). CAP validation was successfully performed on Field II simulations and on tissue-mimicking phantoms. In vivo performance was assessed in a cohort of 59 patients spanning the range of steatosis. In vivo reproducibility was good and similar with both probes. The area under receiver operative characteristic curve was equal to 0.83/0.84 and 0.92/0.91 for the M/XL probes to detect >2% and >16% liver fat, respectively, as assessed by magnetic resonance imaging. Patients can now be assessed simultaneously for steatosis and fibrosis using the FibroScan, regardless of their morphology.